Modulation of specific active immunization against murine melanoma using recombinant cytokines
- 31 December 1996
- journal article
- research article
- Published by Elsevier in Surgical Oncology
- Vol. 5 (5-6) , 221-229
- https://doi.org/10.1016/s0960-7404(96)80025-9
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Immunotherapy Via Gene TherapyJournal of Immunotherapy, 1993
- In vivo inhibition of tumor growth of B16 melanoma by recombinant interleukin 1β: II. Mechanism of inhibition: The role of polymorphonuclear leukocytesCytokine, 1990
- Active specific immunotherapy with vaccinia colon oncolysate enhances the immunomodulatory and antitumor effects of interleukin-2 and interferon α in a murine hepatic metastasis modelCancer Immunology, Immunotherapy, 1990
- In vivo inhibition of tumor growth of B16 melanoma by recombinant interleukin 1? I. Tumor inhibition parallels lymphocyte-activating factor activity of interleukin 1? proteinsCytokine, 1990
- Differential activity of interleukin 1α and interleukin 1β in the stimulation of the immune response in vivoEuropean Journal of Immunology, 1990
- Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2.The Journal of Experimental Medicine, 1985
- T cell growth factor receptors. Quantitation, specificity, and biological relevanceThe Journal of Experimental Medicine, 1981
- The functional relationship of the interleukins.The Journal of Experimental Medicine, 1980
- Two distinct factors are required for induction of T-cell growthNature, 1980
- Non-specific and specific active immunotherapy in a B16 murine melanoma systemJournal of Surgical Oncology, 1979